Want to see IN:PAR full AI Analyst Report?
Top Page
Par Drugs and Chemicals Limited
(PAR)
Select Model
Select Model
Rating:81Outperform
Price Target:
₹145.00
▲(43.66% Upside)
Action:Reiterated
Date:09/06/26
Overall score is supported primarily by strong financial quality—especially the debt-free balance sheet—alongside solid profitability. Technicals add support due to strong momentum and price strength above moving averages, though overbought indicators increase near-term risk. Valuation appears reasonable on P/E, but limited dividend data keeps this component from scoring higher.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet materially reduces financial risk and preserves flexibility for working capital, investment, and other capital-allocation needs. The consistent absence of leverage across five years supports resilience and limits the drag from interest obligations during weaker operating periods.
Negative Factors
Inconsistent revenue growth
The uneven revenue pattern makes medium-term expansion less predictable than a consistently growing profile. Although growth re-accelerated in 2026, the earlier slowdown suggests that demand, product mix, or commercial execution has not yet produced a stable upward trajectory.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet materially reduces financial risk and preserves flexibility for working capital, investment, and other capital-allocation needs. The consistent absence of leverage across five years supports resilience and limits the drag from interest obligations during weaker operating periods.
Read all positive factors
Par Drugs and Chemicals Limited (PAR) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.54B
Dividend Yield0.7%
Average Volume (3M)122.31K
Price to Earnings (P/E)10.8
Beta (1Y)0.91
Revenue Growth4.29%
EPS Growth2.40%
CountryIN
Employees118
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)11.78
Shares Outstanding12,304,636
10 Day Avg. Volume19,218
30 Day Avg. Volume122,309
Financial Highlights & Ratios
PEG Ratio-3.82
Price to Book (P/B)0.86
Price to Sales (P/S)0.93
P/FCF Ratio6.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Par Drugs and Chemicals Limited Business Overview & Revenue Model
Company Description
Par Drugs and Chemicals Limited is an Indian enterprise that focuses on the creation, production, and sale of active pharmaceutical ingredients (APIs) and specialized chemicals. Its comprehensive product line features a diverse array of compounds,...
How the Company Makes Money
null...
Par Drugs and Chemicals Limited Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
92
Very Positive
Cash Flow
77
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.09B | 1.04B | 1.01B | 956.40M | 950.95M | 746.15M |
| Gross Profit | 552.62M | 504.71M | 617.86M | 609.88M | 286.90M | 173.68M |
| EBITDA | 204.31M | 211.32M | 195.01M | 229.53M | 184.46M | 163.61M |
| Net Income | 144.93M | 131.09M | 133.58M | 145.01M | 113.34M | 92.13M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 1.29B | 1.19B | 1.02B | 888.68M | 786.90M |
| Cash, Cash Equivalents and Short-Term Investments | 418.43M | 418.43M | 275.77M | 366.54M | 222.43M | 162.06M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | -1.12B | 172.28M | 204.15M | 159.79M | 176.30M | 188.13M |
| Stockholders Equity | 1.12B | 1.12B | 989.75M | 856.32M | 712.38M | 598.77M |
Cash Flow | ||||||
| Free Cash Flow | 73.74M | 144.71M | 149.34M | 141.69M | 57.44M | 44.13M |
| Operating Cash Flow | 80.95M | 164.32M | 161.60M | 202.49M | 133.77M | 76.15M |
| Investing Cash Flow | -18.16M | -21.66M | -252.37M | -58.38M | -73.38M | -30.18M |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -24.00K | -95.54M |
Par Drugs and Chemicals Limited Technical Analysis
Neutral
100.93
Price Trends
116.36
Positive
103.71
Positive
98.64
Positive
Market Momentum
2.83
Positive
48.95
Neutral
28.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PAR, the sentiment is Neutral. The current price of 100.93 is below the 20-day moving average (MA) of 138.73, below the 50-day MA of 116.36, and above the 200-day MA of 98.64, indicating a neutral trend. The MACD of 2.83 indicates Positive momentum. The RSI at 48.95 is Neutral, neither overbought nor oversold. The STOCH value of 28.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:PAR.
Par Drugs and Chemicals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹1.54B | 10.75 | ― | 0.70% | 4.29% | 2.40% | |
60 Neutral | ₹1.70B | 12.43 | ― | ― | -7.71% | 927.75% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹1.27B | 35.42 | ― | ― | 0.46% | -83.31% | |
49 Neutral | ₹1.78B | 24.13 | ― | 1.09% | 13.51% | -14.80% | |
47 Neutral | ₹517.83M | 102.74 | ― | ― | 9.31% | -82.71% | |
45 Neutral | ₹451.88M | -0.26 | ― | 0.67% | -39.80% | -452.04% |
* General Sector Average
IN:PAR
Par Drugs and Chemicals Limited
126.64
21.11
20.00%
IN:ALPA
Alpa Laboratories Limited
59.54
-29.52
-33.15%
IN:BALPHARMA
Bal Pharma Limited
109.28
27.11
32.99%
IN:BIOFILCHEM
Biofil Chemicals & Pharmaceuticals Ltd.
30.31
-11.40
-27.33%
IN:BROOKS
Brooks Laboratories Limited
55.50
-76.05
-57.81%
IN:VIVIMEDLAB
Vivimed Labs Limited
5.35
0.45
9.18%
Par Drugs and Chemicals Limited Corporate Events
Par Drugs and Chemicals’ 27th AGM Clears All Resolutions with Majority Support
Sep 27, 2026
Par Drugs and Chemicals Limited held its 27th Annual General Meeting on 26 September 2026 in Vadodara, Gujarat, providing shareholders with remote e-voting and on-site ballot options in line with the Companies Act and SEBI listing regulations. An ...
Par Drugs and Chemicals Publishes AGM and E‑Voting Notice in Newspapers
Sep 5, 2026
Par Drugs and Chemicals Limited has published statutory newspaper advertisements announcing the notice and e‑voting details for its 27th Annual General Meeting. The communication, released in The Economic Times and Navgujarat Samay, is part ...
Par Drugs and Chemicals Flags Unclaimed Dividend Shares for Transfer to IEPF
Aug 21, 2026
Par Drugs and Chemicals Limited has notified shareholders and the stock exchange that certain equity shares are liable to be transferred to the Investor Education and Protection Fund, as required under the IEPF Authority Rules, 2016. The move affe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.